PCN29 Time to Next Treatment As a Candidate Surrogate Endpoint for Overall Survival in Previously Untreated Advanced Melanoma Patients Treated with Immune-Checkpoint Inhibitors
Saved in:
| Published in | Value in health Vol. 23; p. S426 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Elsevier Inc
01.12.2020
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1098-3015 1524-4733 |
| DOI | 10.1016/j.jval.2020.08.166 |
Cover
| Author | Gaudin, A.F. Kurt, M. Sofeu, C.L. Rondeau, V. Bellera, C. Italiano, A. Branchoux, S. Moshyk, A. |
|---|---|
| Author_xml | – sequence: 1 givenname: S. surname: Branchoux fullname: Branchoux, S. organization: Bristol Myers Squibb, RUEIL MALMAISON, France – sequence: 2 givenname: C.L. surname: Sofeu fullname: Sofeu, C.L. organization: Bordeaux Population Health Center, ISPED, Centre INSERM U1219, Bordeaux, France – sequence: 3 givenname: A.F. surname: Gaudin fullname: Gaudin, A.F. organization: Bristol-Myers Squibb, Rueil-Malmaison, France – sequence: 4 givenname: M. surname: Kurt fullname: Kurt, M. organization: Bristol Myers Squibb, Princeton, NJ, USA – sequence: 5 givenname: A. surname: Moshyk fullname: Moshyk, A. organization: Bristol-Myers Squibb, Lawrenceville, NJ, USA – sequence: 6 givenname: A. surname: Italiano fullname: Italiano, A. organization: Institut Bergonié Comprehensive Cancer Centre, Bordeaux, France – sequence: 7 givenname: C. surname: Bellera fullname: Bellera, C. organization: Epicene Team (Cancer & Environnement), Bordeaux Population Health Center, ISPED, Centre INSERM U1219, Bordeaux, France – sequence: 8 givenname: V. surname: Rondeau fullname: Rondeau, V. organization: Bordeaux Population Health Center, ISPED, Centre INSERM U1219, Bordeaux, France |
| BookMark | eNqFUV1v0zAUtdCQ2Ap_gCf_gQR_JG6KEFJVDag0tkrrni3HvqHOEnuy3UD_FT9xjsrTJODFPtK95557zr1CF847QOg9JSUlVHzoy35SQ8kIIyVpSirEK3RJa1YV1ZLzi4zJqik4ofUbdBVjTwgRnNWX6Pduc8tWeG9HwMnjW_iV8D6ASiO4hNcRK7xRzlijEuD7Ywj-x4yunXnyNnd0PuC7CYIahrk82bwGtg7vAkzWH-Nwwg8uzQPB4LWZlNMZfIdBOT8qvFPJZqF41syVnzYd8HYcjw6KzQH041lm6w62tcmH-Ba97tQQ4d2ff4EevlzvN9-Km7uv2836ptA5BFGwWtCuXbVCV1XVCdFwU5OqYxpA19wIRbqOa8oU1a1ZVnpJmG5VI7pMpkZxvkDsPFcHH2OATj4FO6pwkpTIOXPZyzlzOWcuSSNz5pn06UyCvNlkIcios79s2QbQSRpv_03__IKuB-usVsMjnCD2_hhc9iypjEwSeT8fdb4pI5xVLL8L9PHvA_6n_gyGtrhn |
| ContentType | Journal Article |
| Copyright | 2020 |
| Copyright_xml | – notice: 2020 |
| DBID | 6I. AAFTH AAYXX CITATION |
| DOI | 10.1016/j.jval.2020.08.166 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef |
| DatabaseTitle | CrossRef |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1524-4733 |
| EndPage | S426 |
| ExternalDocumentID | 10_1016_j_jval_2020_08_166 S1098301520324220 1_s2_0_S1098301520324220 |
| GroupedDBID | --- --K --M .1- .3N .FO .GA .Y3 .~1 0R~ 10A 123 1OC 1P~ 1~. 29Q 31~ 36B 4.4 44B 457 4G. 51W 51X 52N 52P 52R 52S 52X 53G 5LA 5VS 66C 6PF 7-5 7PT 8-1 8P~ 8UM AAEDT AAEDW AAFJI AAFWJ AAIKJ AAKOC AALRI AAMMB AAOAW AAPFB AAQFI AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABCQN ABDBF ABEML ABIVO ABJNI ABMAC ABMMH ABMZM ABWVN ABXDB ACDAQ ACGFS ACHQT ACIEU ACPRK ACRLP ACRPL ACUHS ACVFH ACXQS ADBBV ADCNI ADEZE ADFHU ADMUD ADNMO ADVLN AEBSH AEFGJ AEIPS AEKER AENEX AEUPX AEVXI AEXQZ AEYQN AFBPY AFEBI AFJKZ AFPUW AFRHN AFTJW AFXIZ AFZJQ AGCQF AGHFR AGQPQ AGTHC AGUBO AGXDD AGYEJ AIDQK AIDYY AIEXJ AIGII AIIAU AIIUN AIKHN AITUG AJAOE AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX AOMHK APXCP ASPBG AVARZ AVWKF AXJTR AXLSJ AZFZN BAWUL BFHJK BKOJK BLXMC BNPGV BY8 CAG CO8 COF CS3 DCZOG DIK DU5 EAD EAP EBS EFJIC EFKBS EJD EMB EMK EMOBN ESX F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN GBLVA HF~ HVGLF HZI HZ~ IHE IXB KOM LH4 M41 MO0 N9A O-L O9- OAUVE OIG OK1 OVD P-8 P-9 P2P PC. PQQKQ PRBVW Q38 QB0 R2- ROL SDF SEL SES SPCBC SSB SSF SSH SSO SSZ SV3 T5K TEORI TUS W99 WIN WYUIH XG1 YFH Z5R ~G- 0SF 6I. AACTN AAFTH AAHHS ABVKL ACCFJ AEEZP AEQDE AFCTW AFKWA AIWBW AJBDE AJOXV AMFUW NCXOZ RIG SUPJJ AAIAV ABLVK ABYKQ AJBFU AKYCK EFLBG IXIXF LCYCR AAYXX AGRNS CITATION |
| ID | FETCH-LOGICAL-c2026-2561fb9b6c444f6683d504f2ceec53d6a0ff3c12a1cbd74c702cba86f0261da33 |
| IEDL.DBID | IXB |
| ISSN | 1098-3015 |
| IngestDate | Tue Jul 01 04:22:01 EDT 2025 Fri Feb 23 02:40:15 EST 2024 Sun Feb 23 10:18:50 EST 2025 Tue Aug 26 19:01:43 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| License | http://www.elsevier.com/open-access/userlicense/1.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c2026-2561fb9b6c444f6683d504f2ceec53d6a0ff3c12a1cbd74c702cba86f0261da33 |
| OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S1098301520324220 |
| ParticipantIDs | crossref_primary_10_1016_j_jval_2020_08_166 elsevier_sciencedirect_doi_10_1016_j_jval_2020_08_166 elsevier_clinicalkeyesjournals_1_s2_0_S1098301520324220 elsevier_clinicalkey_doi_10_1016_j_jval_2020_08_166 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | December 2020 |
| PublicationDateYYYYMMDD | 2020-12-01 |
| PublicationDate_xml | – month: 12 year: 2020 text: December 2020 |
| PublicationDecade | 2020 |
| PublicationTitle | Value in health |
| PublicationYear | 2020 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| SSID | ssj0006325 |
| Score | 2.2843907 |
| SourceID | crossref elsevier |
| SourceType | Index Database Publisher |
| StartPage | S426 |
| SubjectTerms | Internal Medicine |
| Title | PCN29 Time to Next Treatment As a Candidate Surrogate Endpoint for Overall Survival in Previously Untreated Advanced Melanoma Patients Treated with Immune-Checkpoint Inhibitors |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1098301520324220 https://www.clinicalkey.es/playcontent/1-s2.0-S1098301520324220 https://dx.doi.org/10.1016/j.jval.2020.08.166 |
| Volume | 23 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfGkBAvCAaI8lHdA9oLC43z4SSPpdrUgloqrZX6Zjl2rGUrSdV0k_rC38SfyF0-NhATSLwlsU9OfPZ9OPe7Y-y9G2Wa88g6EYpFJ_CscBKFjqswkU1tkhgvIqDwdCbGy-DzKlwdsFGHhaGwylb2NzK9ltbtk0E7m4NNng_OuZvEuDxDqgEeeB757YQqJRDf6tOtNBZ-XXiVOjvUuwXONDFel8hN9BE9l9J48jpT4j3K6ReFc_aUPWktRRg2L_OMHWTFEXs0bf-FH7HjeZN1en8CizsQVXUCxzC_y0e9f85-zEczLwECe8CuhBmKY1h08eUwrEDBiMAt5PvD-fV2W9LRGpwWZlPm2APNWvh6Q2dXa2q-yfFzIC-Asj9RBO16D8uiDljPDAzbmAKYZmtVlN8UzJvMrVUzJrbQ0S9MCJeSOaOLTF81w0yKizzNqfjPC7Y8O12Mxk5bqMHROHnCQbOJ2zRJhQ6CwAoR-yZ0A-uhAtahb4RyrfU19xTXqYkCHbmeTlUsLDmARvn-S3ZYlEX2ioE2SlmDVlrEk8D6boKXXIeoyVUcayN67EPHIblp8nHILlDtUhI_JfFTurFEfvaY3zFRdkhTlI0S1cVfqaL7qLKq3d6V5LLypCv_WII9Ft5S_raK_zHi6_-ke8Me010TXvOWHe6219k7NJJ2aZ89-Pid99nD4eTLeNav98RPe0MU-A |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9tAEF6CA20vpU1b6qaPOZRcGmGtHivpaESC3cSuITbktqx2tUSpKxnLCfhf5Sd2xpKSloYWehNaDStpVvNYfd8MY5_dKNecR9aJ0Cw6gWeFkyhMXIWJbGaTxHgREYUnUzFaBF8vw8s9lnZcGIJVtra_sek7a92eGbRvc7AqisEFd5MYl2dIPcADz8O8fT-gptY9tj8cn42m9wZZ-Lveq3S9QwItd6aBeV2jQjFN9Fyq5Ml3xRIf8U-_-JzTF-x5GyzCsLmfl2wvLw_Yk0n7O_yAHc2awtPbY5g_8KjqYziC2UNJ6u0rdjdLp14CxPeATQVTtMgw7yDmMKxBQUr8Fkr_4eJmva5odw1OSrOqCrwCI1v4dkvbV0savi3wcaAogQpAEYh2uYVFucOs5waGLawAJvlSldUPBbOmeGvdzIkjtPsLY6Km5E56levvzTTj8qrICur_85otTk_m6chpezU4Gl-ecDBy4jZLMqGDILBCxL4J3cB66IN16BuhXGt9zT3FdWaiQEeupzMVC0s5oFG-_4b1yqrM3zLQRilrMFCLeBJY303wkOsQnbmKY21En33pNCRXTUkO2WHVriXpU5I-pRtL1Gef-Z0SZUc2RfMo0WP8VSp6TCqv2y-8llzWnnTlH6uwz8J7yd8W8j9mfPefcp_Y09F8ci7Px9OzQ_aMRhq0zXvW26xv8g8YM22yj-038RNHfBad |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=PCN29+Time+to+Next+Treatment+As+a+Candidate+Surrogate+Endpoint+for+Overall+Survival+in+Previously+Untreated+Advanced+Melanoma+Patients+Treated+with+Immune-Checkpoint+Inhibitors&rft.jtitle=Value+in+health&rft.au=Branchoux%2C+S.&rft.au=Sofeu%2C+C.L.&rft.au=Gaudin%2C+A.F.&rft.au=Kurt%2C+M.&rft.date=2020-12-01&rft.issn=1098-3015&rft.volume=23&rft.spage=S426&rft_id=info:doi/10.1016%2Fj.jval.2020.08.166&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_jval_2020_08_166 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F10983015%2FS1098301520X00155%2Fcov150h.gif |